These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8124745)

  • 1. [D-Trp-6 gonadotropin analog releasing hormone (Decapeptyl-Depot)-- the drug of choice in central idiopathic precocious puberty].
    Hníková O; Janecková M; Finková M
    Cesk Pediatr; 1994; 49(1):22-4. PubMed ID: 8124745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Growth, development and prediction of body height in children with central precocious puberty after 3 years of therapy with Decapeptyl-Depot, a slow-releasing GnRH agonist].
    Hümmelink R; Oostdijk W; Partsch CJ; Odink RJ; Drop SL; Sippell WG
    Cesk Pediatr; 1994; 49(1):7-12. PubMed ID: 8124755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group.
    Partsch CJ; Hümmelink R; Peter M; Sippell WG; Oostdijk W; Odink RJ; Drop SL
    Horm Res; 1993; 39(3-4):111-7. PubMed ID: 8262471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison between complete and incomplete suppression of the hypophyseal-gonadal axis in girls with central precocious puberty: effect on growth and prospective final height].
    Partsch CJ; Hümmelink R; Sippell WG; Oostdijk W; Odink RJ; Drop SL
    Monatsschr Kinderheilkd; 1993 Dec; 141(12):935-9. PubMed ID: 8114776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Long-term therapy of true precocious puberty in girls using Decapetyl-Depot, a superactive gonadoliberin agonist in depot microcapsulated form].
    Sippell WG; Partsch CJ; Hümmelink R; Lorenzen F
    Cesk Pediatr; 1994; 49(1):13-8. PubMed ID: 8124743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center.
    Chung LY; Kang E; Nam HK; Rhie YJ; Lee KH
    J Korean Med Sci; 2021 Aug; 36(34):e219. PubMed ID: 34463062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth, bone maturation and height prediction after three years of therapy with the slow release GnRH-agonist Decapeptyl-Depot in children with central precocious puberty.
    Hümmelink R; Oostdijk W; Partsch CJ; Odink RJ; Drop SL; Sippell WG
    Horm Metab Res; 1992 Mar; 24(3):122-6. PubMed ID: 1533604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty.
    Carel JC; Blumberg J; Seymour C; Adamsbaum C; Lahlou N;
    Eur J Endocrinol; 2006 Jan; 154(1):119-24. PubMed ID: 16382000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative calcaneal ultrasound parameters and bone mineral density at final height in girls treated with depot gonadotrophin-releasing hormone agonist for central precocious puberty or idiopathic short stature.
    Kapteijns-van Kordelaar S; Noordam K; Otten B; van den Bergh J
    Eur J Pediatr; 2003 Nov; 162(11):776-80. PubMed ID: 13680381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation.
    Martínez-Aguayo A; Hernández MI; Beas F; Iñiguez G; Avila A; Sovino H; Bravo E; Cassorla F
    J Pediatr Endocrinol Metab; 2006 Aug; 19(8):963-70. PubMed ID: 16995580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triptorelin (Triptodur) for central precocious puberty.
    Med Lett Drugs Ther; 2018 Jan; 60(1537):7-8. PubMed ID: 29294465
    [No Abstract]   [Full Text] [Related]  

  • 13. The Influence of GnRH Analog Therapy on Growth in Central Precocious Puberty.
    Głąb E; Wikiera B; Bieniasz J; Barg E
    Adv Clin Exp Med; 2016; 25(1):27-32. PubMed ID: 26935495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Improvement in the prognosis for growth in a boy with central precocious puberty and growth hormone deficiency treated concurrently with growth hormone and D-Trp-6-LHRH gonadoliberin analog].
    Snajderová M; Lebl J; Zemková D; Kolousková S; Pechová M
    Cesk Pediatr; 1994; 49(1):25-8. PubMed ID: 8124746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triptorelin depot for the treatment of children 2 years and older with central precocious puberty.
    Bertelloni S; Mucaria C; Baroncelli GI; Peroni D
    Expert Rev Clin Pharmacol; 2018 Jul; 11(7):659-667. PubMed ID: 29957076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central precocious puberty in girls: internal genitalia before, during, and after treatment with long-acting gonadotropin-releasing hormone analogues.
    Jensen AM; Brocks V; Holm K; Laursen EM; Müller J
    J Pediatr; 1998 Jan; 132(1):105-8. PubMed ID: 9470009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term experiences with a long-acting gonadotropin releasing hormone analog in therapy of central precocious puberty: effect on body growth].
    Hofmann-Ehrhart B; Schulz U; Kluge M; Wandl-Vergesslich K; Waldhauser F
    Wien Klin Wochenschr; 1995; 107(14):413-7. PubMed ID: 7668000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty.
    Carel JC; Roger M; Ispas S; Tondu F; Lahlou N; Blumberg J; Chaussain JL
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1973-8. PubMed ID: 10372696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
    Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
    J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variations in pituitary-gonadal suppression during intranasal buserelin and intramuscular depot-triptorelin therapy for central precocious puberty. Belgian Study Group for Pediatric Endocrinology.
    Heinrichs C; Craen M; Vanderschueren-Lodeweyckx M; Malvaux P; Fawe L; Bourguignon JP
    Acta Paediatr; 1994 Jun; 83(6):627-33. PubMed ID: 7919761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.